Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.

By M. Coghlan, A. Culbert, D. Cross, S. Corcoran, J. Yates, N. Pearce, G. Murphy, P. Carter, L. Roxbee Cox, D. Mills and 7 more. Chemistry and Biology, 2000

905 citations recorded by the source corpus.

Subfields: Molecular Biology, Rheumatology, Surgery

View Paper: https://www.semanticscholar.org/paper/274494fb1fe8c5960959451560aa81f813adca16

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. D. Alessi
2. M. Goedert
3. J. Isaac
4. Peng Jin
5. Xinyu Zhao
6. Keith E. Szulwach
7. G. Collingridge
8. P. Cohen

In Surgery

1. D. Alessi

Citations in the corpus

• GSK3 inhibitors: development and therapeutic potential (2004, background): “fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=2997,2998">glycogen synthase and accelerated the conversion of glucose to glycogen in a human liver cell lin”
• Pharmacological inhibitors of glycogen synthase kinase 3. (2004, neutral): “SB415286 Anilinomaleimide 0.078 (a); 0.13 (a/b)d 0.900d [ 53 ,81]”
• PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? (2001, background): “Furthermore, selective and potent small-molecule inhibitors of GSK3 have recently been developed, termed SB-415286 and SB-216763 (Coghlan et al., 2000), and these have also been shown, together with lithium, a less specific GSK3 inhibitor, to protect both central and peripheral nervous system neuron”
• Lithium induces autophagy by inhibiting inositol monophosphatase (2005, methodology): “Transfection mixture was replaced after 4 h incubation at 37 C by various compounds, such as 10 mM LiCl, 0.2 M rapamycin, 10 mM 3-MA, 10 M lactacystin, 50 M CBZ, 1 mM myo-inositol (all from Sigma-Aldrich), 10 mM NaCl (BDH), 10 M SB216763 (Tocris), 100 M L-690,330 (Tocris), or 24 M prolyl endopeptida”
• Wnt/β-catenin signaling and disease. (2012, neutral): “SB-216763 GSK3 inhibitor activates (Coghlan et al., 2000) BIO(6-bromoindirubin-30-oxime) GSK3 inhibitor activates (Sato et al.”
• LTP inhibits LTD in the hippocampus via regulation of GSK3beta. (2007, positive): “To determine whether GSK3  is involved in synaptic plasticity in the brain, we tested the effects of the highly selective GSK3 inhibitor 3-[(3-chloro-4-6 hydroxyphenyl)amino]-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione (SB415286) (Coghlan et al., 2000) in rat hippocampal slices.”
• Fragile X Mental Retardation Protein Regulates Proliferation and Differentiation of Adult Neural Stem/Progenitor Cells (2010, background): “In addition, treatment of Fmr1 KO aNPCs with a well-established GSK3b inhibitor SB216763 [50] could enhance the Wnt PLoS Genetics | www.plosgenetics.org 7 April 2010 | Volume 6 | Issue 4 | e1000898 signaling pathway (Figure S9A) and partially rescue the neuronal (Figure 6C and 6D) and astrocyte (Fig”
• Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis (2005, background): “In support of this, GSK3 inhibitors stimulate hepatic glycogen synthase (Coghlan et al, 2000; Cline et al, 2002).”